S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry

Merck is an A+ credit, a global oncology powerhouse, and still, about half its 2024 pharma revenue came from a single product: Keytruda, a product whose loss of exclusivity will hit around 2028 in the U.S. S&P Global Ratings calls that kind of concentration a “material weakness.” Merck isn’t alone. A new S&P analysis of… The post S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry appeared first on Drug Discovery and Development.

Continue reading →